An interventional study of Suboccipital release in Fibromyalgia, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Fibromyalgia by Cairo University — 9 open to participants now, 9 under way, none of them phase 3. Fibromyalgia · Cairo University.
Among the 13 studies in Fibromyalgia by Cairo University, this one is the 9th largest by planned enrollment, is one of 4 that started in 2024, is one of 13 with no phase, and was the 8th registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →9 of the 13 studies in Fibromyalgia by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 16–70
Cairo University · Sites in Egypt
Ages 18–65 · Women only
Cairo University · Sites in Egypt
Ages 18–70
Cairo University · Sites in Egypt
Ages 20–45 · Women only
Cairo University · Sites in Egypt
By country, each count listing its studies:
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 20 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 52 across the 13 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
2 of the studies in Fibromyalgia by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07390851Cairo UniversityMagnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG. | 2026-11-26 |
| NCT07572994Cairo UniversityEvaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Fibromyalgia by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was designed to examine the efficacy of suboccipital release in Patients With FMS and to provide preliminary evidence regarding its effects on pain and QOL by objectively measuring Cortisol level in FMS patien
Forty female patients with FM ( age : 20- 45 Years ) participated in the study after suing the consent form . Participants were randomly allocated assigned into 2 equal groups ( control group [ G1 ] and study [G2 ] ) . Group
1 received selected physical therapy programme. Group 2 recieved suboccipital release. All participants were assessed for cortisol and pain level by using visual analogues scale and neck disability scale. Also participants were assessed by pressure algometer for pain intensity. Participants were assessed for QOL by FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQR) . treatment was done 3 sessions per weeks for successive 6 weeks pre and post assessment for all valuable were Done
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
American College of Rheumatology criteria for fibromyalgia [1]
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Suboccipital release
Other: Suboccipital release
The ptients in this group recieve suboccipital release. The patient is positioned in a supine (lying on their back) position, allowing full relaxation of the cervical spine. The therapist places their fingertips or hands under the patient's occiput, making contact with the suboccipital muscles. Using gentle, sustained pressure, the therapist allows the weight of the head to create a release, often holding for 1-5 minutes. Subtle adjustments may be made, such as slight traction or rocking, to facilitate myofascial release and relaxation.
Cortisol level
Changes in pain from baseline to six weeks after begining of intervention
Time frame: Six weeks after begining of intervention
Fibromyalgia impact questionair
Changes of quality of life from baseline to six weeks after begining of interventio
Time frame: Six weeks after begining of intervention
Started Feb 2024 (actual). Primary completion is estimated for Apr 2025, 14 months after the start.
Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 14 months is close to that.
Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.